Market-Based Licensing for HPV Vaccines in Developing Countries

14 Pages Posted: 22 Nov 2009 Last revised: 11 Feb 2014

See all articles by Kevin Outterson

Kevin Outterson

Boston University School of Law

Aaron S. Kesselheim

Brigham and Women's Hospital/Harvard Medical School

Date Written: January 1, 2008

Abstract

Human papillomavirus (HPV) vaccines hold great promise for preventing cervical cancer, but 93 percent of mortality worldwide occurs in low- and middle-income countries, where high vaccine costs can restrict dissemination. Current models for promoting international access to health care innovations include differential pricing, advance market commitments, and voluntary and compulsory licensing. Some of these mechanisms have been effective, but much room for improvement remains. We discuss the usefulness of a new type of license that uses market forces to lower prices through generic competition in low- and middle-income countries while ensuring that pharmaceutical companies are appropriately reimbursed for their research and development.

Keywords: Compulsory license, HPV vaccine, generic open license, access to vaccines

Suggested Citation

Outterson, Kevin and Kesselheim, Aaron S., Market-Based Licensing for HPV Vaccines in Developing Countries (January 1, 2008). Health Affairs, Vol. 27, No. 1, 2008, Available at SSRN: https://ssrn.com/abstract=1510885

Kevin Outterson (Contact Author)

Boston University School of Law ( email )

765 Commonwealth Avenue
Boston, MA 02215
United States

Aaron S. Kesselheim

Brigham and Women's Hospital/Harvard Medical School ( email )

1620 Tremont St
Suite 3030
Boston, MA 02120
United States
617-278-0930 (Phone)
617-232-8602 (Fax)

HOME PAGE: http://www.PORTALresearch.org

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
34
Abstract Views
770
PlumX Metrics